Patents Assigned to Hadasit Medical Research Services and Development Ltd.
  • Patent number: 11801220
    Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 31, 2023
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Ruth Gabizon, Haim Ovadia, Oded Abramsky, Shlomo Magdassi, Liraz Larush
  • Patent number: 11746324
    Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: September 5, 2023
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan Reubinoff, Orna Singer
  • Patent number: 11718666
    Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: August 8, 2023
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat Safadi
  • Publication number: 20230157896
    Abstract: The present invention relates to a device for repair of a region within an ear via a natural orifice, the device comprising a body. The body comprises a first port for visibly identifying the region to be sealed, the region being inside the ear; and a second port through which a seal can be introduced into the ear through the device. The region comprises a perforation of a tympanic membrane of the ear and the device is a speculum. The present invention also relates to method for repairing a perforation in a tympanic membrane using the same device.
    Type: Application
    Filed: March 11, 2021
    Publication date: May 25, 2023
    Applicants: National University of Singapore, Hadasit Medical Research Services And Development Ltd, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
    Inventors: Menachem Gross, Shlomo Magdassi, Yin Chiang Boey, Ngeow Khing Chia
  • Publication number: 20230078665
    Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Application
    Filed: November 10, 2022
    Publication date: March 16, 2023
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Abraham RUTENBERG, Ronny UZANA, Michal LOTEM, Arthur MACHLENKIN, Galit EISENBERG, Tamar PERETZ-YABLONSKY, Shoshana FRANKENBURG, Roni ENGELSTEIN
  • Patent number: 11583537
    Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising use of artemisone in combination with at least one antiviral compound selected from maribavir, cidofovir, brincidofovir, valganciclovir, and letermovir, and the combination provides a synergistic anti-viral effect. The invention also provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisone in combination with ganciclovir, wherein the molar ratio between artemisone and ganciclovir is about 1:100 to 100:1, and the combination provides a synergistic anti-viral effect. Pharmaceutical compositions comprising artemisone and at least one of said antiviral compounds are provided as well.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: February 21, 2023
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Dana Wolf
  • Patent number: 11565091
    Abstract: A method for influencing cerebral perfusion in a patient by modifying a volume of a volume adaptor introduced into a cerebral ventricle of the patient, the method comprising identifying a timing of a cerebral blood inflow and/or outflow in a cardiac activity of the patient, modifying a volume of the volume adaptor in synchronization to the identified timing of the cerebral blood flow, to an amount sufficient to modify an intracranial pressure in the cerebral ventricle, such that a flow of the cerebral blood flow is enhanced. In some exemplary embodiments of the invention, the inflation duration of the volume adapter is short relative to the cardiac cycle.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: January 31, 2023
    Assignees: Ramot at Tel-Aviv University Ltd., Tel HaShomer Medical Research Infrastructare and Services Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Ofer Barnea, Omer Doron
  • Patent number: 11530251
    Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: December 20, 2022
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Abraham Rutenberg, Ronny Uzana, Michal Lotem, Arthur Machlenkin, Galit Eisenberg, Tamar Peretz-Yablonsky, Shoshana Frankenburg, Roni Engelstein
  • Patent number: 11478453
    Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: October 25, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Iris Lavon Ben Moshe, Tamar Canello Avramovitch
  • Patent number: 11466323
    Abstract: A digital droplet PCR method of analyzing the methylation status of methylation sites of a double-stranded DNA molecule which comprises at least two methylation sites per single strand of the double-stranded DNA molecule is disclosed.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: October 11, 2022
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Yuval Dor, Ruth Shemer, Benjamin Glaser, Judith Magenheim
  • Publication number: 20220233477
    Abstract: A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.
    Type: Application
    Filed: June 11, 2020
    Publication date: July 28, 2022
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Etti BEN-SHUSHAN
  • Publication number: 20220225612
    Abstract: The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.
    Type: Application
    Filed: November 22, 2021
    Publication date: July 21, 2022
    Applicants: NOBIO Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Nathan Zaltsman, Ervin Itzhak Weiss, Nurit Beyth
  • Publication number: 20220213445
    Abstract: A culture of human pluripotent stem cells (hPSCs) is disclosed. In the culture, more than 50% of the hPSCs are formative hPSCs and are capable of renewing. Uses thereof are also disclosed.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 7, 2022
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Michal GROPP
  • Publication number: 20220184154
    Abstract: A method of treating bacterial vaginosis in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a composition which comprises between three and twenty species of bacteria or a secretion thereof, wherein at least 70% of the bacteria of the composition are of the species Lactobacillus crispatus, thereby treating the bacterial vaginosis.
    Type: Application
    Filed: February 28, 2022
    Publication date: June 16, 2022
    Applicants: Yeda Research and Development Co. Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Eran ELINAV, Yotam COHEN, Ahinoam LEV-SAGIE, Debra GOLDMAN-WOHL
  • Patent number: 11298151
    Abstract: Device for accessing a pericardial space of a subject in need thereof, the device including a tubular member having an atraumatic distal end and a thread formed on, and at least partially around, the outer surface of the tubular member, proximally to the distal end; wherein the thread is configured to cut, puncture and/or penetrate a pericardium.
    Type: Grant
    Filed: June 17, 2018
    Date of Patent: April 12, 2022
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Ran Eliaz, Yonathan Avraham Demma, Ziv Menshes, Or Hazan, Eva Abramov, Yaakov Nahmias, Amnon Buxboim, Yoav Kan-Tor, Yoav Mintz, Elchanan Fried
  • Patent number: 11273201
    Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: March 15, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
  • Patent number: 11261433
    Abstract: An article of manufacture is disclosed which comprises at least two populations of autosomal-identical induced pluripotent stem cells (iPSCs), wherein the complement of sex chromosomes of the first population of the at least two populations is non-identical to the complement of sex chromosomes of the second population of the at least two populations. Uses thereof and methods of generating same are also disclosed.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: March 1, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Ithai Waldhorn, Benjamin Eithan Reubinoff
  • Patent number: 11246912
    Abstract: The present invention is directed to a method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an adropin stimulating agent. Further provided are a method and a kit for diagnosing or prognosing liver metastases in a subject.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: February 15, 2022
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Rinat Abramovitch, Esther Goldlist
  • Patent number: 11241147
    Abstract: A guided tracheal intubation system using an autonomous modulated light source, outputting modulated illumination at a constant level, and externally applied to the subject's larynx region. An optical imaging system receives a video stream from within the subject's throat, including modulated illumination from the subject's trachea. A display control system performs signal processing on the modulated content of the images, and outputs frames of those images in which the intensity level of illumination from the trachea can be controlled without any need to change the illumination output from the modulated light source. The light source has no connection with the rest of the system, and need contain no more than a battery, a power supply circuit and a light source. It can therefore be of low cost and can be made disposable, such as in the form of an adhesive patch applied to the subject's neck.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: February 8, 2022
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Itai Hayut, Elchanan Fried, Yaakov Nahmias, Tommy Weiss-Sadan, Ariel Shrem
  • Patent number: 11230696
    Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: January 25, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan Reubinoff, Orna Singer